Difelikefalin
Kappa Opioid Receptor Agonist — VARIOUS
Also known as: CR845, difelikefalin acetate, FE202845, kapruvia, korsuva, MR13A9
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Difelikefalin is an onp drug in the Kappa Opioid Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Opioid kappa Receptor Agonists. DrugCentral lists 2 molecular targets, including Oprk1 and OPRK1. Recorded indications include Pruritus associated with chronic kidney disease (CKD-aP).
- Approval status: onp (first approved 2021 by the FDA).
- Drug class: Kappa Opioid Receptor Agonist.
- Mechanism of action: Opioid kappa Receptor Agonists.
- Molecular targets: Oprk1 and OPRK1 (2 listed in DrugCentral).
- Indications: Pruritus associated with chronic kidney disease (CKD-aP).
- ATC code: V03AX04 (Other therapeutic products).
- Molecular formula: C36H53N7O6; molecular weight 679.86 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Pruritus associated with chronic kidney disease (CKD-aP)
Mechanism & targets
| Mechanism of action (MoA) | Opioid kappa Receptor Agonists |
|---|---|
| Established pharmacologic class | Kappa Opioid Receptor Agonist |
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Kappa-type opioid receptor | Oprk1 | agonist | EC50 10.32 |
| Kappa-type opioid receptor | OPRK1 | agonist | Ki 9.49 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2022-04-25 | EMA | — | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE | |
| 2021-08-23 | FDA | — | CARA THERAPEUTICS INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
V03AX04 | VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Other therapeutic products |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Somnolence | 85.6 |
| Mental status changes | 75.3 |
| Dizziness | 58.5 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Difelikefalin is on its molecule page.
| Molecular formula | C36H53N7O6 |
|---|---|
| Molecular weight | 679.86 g/mol |
| CAS number | 1024828-77-0 |
| InChIKey | FWMNVWWHGCHHJJ-SKKKGAJSSA-N |
| PubChem CID | 24794466 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Difelikefalin used for?
DrugCentral lists the following indications for Difelikefalin: Pruritus associated with chronic kidney disease (CKD-aP).
How does Difelikefalin work?
Difelikefalin is classified as Opioid kappa Receptor Agonists; its molecular targets in DrugCentral include Oprk1 (agonist) and OPRK1 (agonist).
When was Difelikefalin first approved?
Difelikefalin was first approved by the FDA in 2021.
What drug class does Difelikefalin belong to?
Difelikefalin is in the Kappa Opioid Receptor Agonist class.
What is the chemical formula of Difelikefalin?
Difelikefalin has the molecular formula C36H53N7O6 and a molecular weight of 679.86 g/mol.
Browse: all drugs starting with D · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5470 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3989915 — compound record and bioactivity
- PubChem CID 24794466 — chemical identifiers
- DrugBank DB11938 — drug record
- FDA UNII NA1U919MRO — substance identity
- DailyMed: FDA labels for Difelikefalin — current prescribing information (label search)
- UniProt P41145 (OPRK1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.